KCCure Evidence Based, Patient Driven Kidney Cancer Research Grants
A core feature of our mission is to engage with the patient community to identify kidney cancer research priorities and ensure that research grant funding is geared toward filling those gaps.
KCCure Kidney Cancer Research Process
All grant proposals go through a rigorous peer review process aimed at identifying the best and most promising research that will provide the greatest opportunity to advance the understanding of kidney cancer and improve management and treatment of the disease
KCCure Kidney Cancer Scientific Advisory Board
Our scientific advisory board is made up of the top leaders in the field of kidney cancer research; including leaders from both of the NCI designated Kidney Cancer Specialized Programs of Research Excellence (Spore), leaders in the field of medical oncology, urological oncology, pathology, basic research and pyscho-oncology.
KCCure Chromophobe Grant
The KCCure Chromophobe Grant is a patient-driven, peer-reviewed research award aimed at prioritizing innovative scientific research in chromophobe renal cell carcinoma. The grant provides $50,000 for one year of research, paid in a single installment
The program was launched in 2021, with the first award announced in March 2022. The application period for new proposals is open now and will close on January 20, 2023. Click here for the full RFP.
KCCure Innovation Awards
In 2017, KCCure announced the innaugural Kidney Cancer Innovation Research Grant Award for cutting edge, innovative scientific research in kidney cancer.
Since then, $400,000 in Innovation Research Grants have been awarded to top institutions including Dana Farber, MD Anderson, UTSouthwestern, the University of North Carolina, the National Cancer Institute, and Thomas Jefferson University.
2017 Innovation Award Winner – Wayne A. Marasco, MD, PhD, Dana-Farber Cancer Institute, Harvard Medical School. CAR T Cell Factories that Change the Tumor Microenvironment to Achieve RCC Cures.
2018 Innovation Award Winner – Qing Zhang, MD, PhD, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill. TBK1 Serves as a Novel Therapeutic Target in Kidney Cancer with VHL Loss.
For more information:
Information about new awards will be updated here as RFPs are released. If you’re a researcher and you’d like to discuss funding opportunities with KCCure, contact us at firstname.lastname@example.org.